← Back to Search

Device

Tumor Treating Fields Therapy for Small Cell Lung Cancer

Phase 2
Waitlist Available
Led By Timur Mitin, MD
Research Sponsored by OHSU Knight Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up death or last follow up following start of ttfields therapy, whichever comes first (assessed at 6, 12, 24, 36 and 60 months)
Awards & highlights

Study Summary

This trial will study a new cancer treatment called Optune-Tumor Treating Fields (TTFields). The treatment will be given to people with small cell lung cancer that has spread to the brain, in order to try to prevent the cancer from growing.

Eligible Conditions
  • Small Cell Lung Cancer
  • Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~death or last follow up following start of ttfields therapy, whichever comes first (assessed at 6, 12, 24, 36 and 60 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and death or last follow up following start of ttfields therapy, whichever comes first (assessed at 6, 12, 24, 36 and 60 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Small Cell Lung Cancer (SCLC) Brain Metastases at 6 Months
Secondary outcome measures
Change in Quality of Life Over Time: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30)
Incidence of Cognitive Adverse Events (AEs) Using Mini Mental State Exam (MMSE)
Incidence of SCLC Brain Metastases
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Prevention (TTFields therapy, questionnaire)Experimental Treatment2 Interventions
Patients undergo TTFields therapy over 18-24 hours daily. Cycles repeat every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tumor Treating Fields Therapy
2018
Completed Early Phase 1
~30

Find a Location

Who is running the clinical trial?

OHSU Knight Cancer InstituteLead Sponsor
231 Previous Clinical Trials
2,090,665 Total Patients Enrolled
NovoCure Ltd.Industry Sponsor
57 Previous Clinical Trials
4,721 Total Patients Enrolled
Oregon Health and Science UniversityOTHER
979 Previous Clinical Trials
7,386,458 Total Patients Enrolled
~1 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top